September 6th, 2019

Podcast 232: Basic organic chem and drug pricing

(No Ratings Yet)

You surely remember “O-chem” — those late-night undergraduate hours spent grappling with benzene rings and alkanes and all the rest. Well, it turns out that drug makers were paying close attention to things like racemic mixtures and enantiomers. The manufacturers usually release their products as racemic mixtures and then, when patents are about to expire, an enantiomer appears. Voila! New drug, new price!

Dr. Joseph Ross and his crew looked at the implications to Medicare spending of all this. They published an interesting letter in the Annals of Internal Medicine detailing how much money the system could save if we stuck with the racemic mixtures. How much? Well, on the order of $15 billion over 5 to 6 years.

Links:

Annals of Internal Medicine letter

NEJM Journal Watch Pediatrics and Adolescent Medicine coverage of albuterol vs. levalbuterol

 

One Response to “Podcast 232: Basic organic chem and drug pricing”

  1. Lee M. Ciccarelli says:

    Note levofloxacin more potent for pneumonia than Ofloxacin

    Lexapro escitalopram more effective than celexa citalopram
    R enantiomer inhibits the active L
    Stahl prescribers guide sixth edition page 255

Leave a Reply

Your email address will not be published. Required fields are marked *

Note: This is a moderated forum. By clicking on the "Submit Comment" button below, you agree to abide by the NEJM Journal Watch Terms of Use.

Our physician bloggers cannot respond to requests for personal medical advice, and recommend patients discuss health issues with their individual physicians.

Clinical Conversations

About the Podcast

To subscribe:

Comments, suggestions, and story ideas welcome. Learn more about Clinical Conversations.